Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldesleukin + GD2Bi-aATC + Sargramostim|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|GD2Bi-aATC||anti-CD3 x hu3F8 bispecific antibody-armed ATC||GD2Bi-aATC are autologous T-cells that have been “armed” with bispecific antibodies that target both GD2 and CD3, resulting in cytotoxicity of GD2-expressing tumor cells by cross-linking activated T-cells to GD2-positive tumor cells, and may also enhance CTL-mediated response tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02173093||Phase Ib/II||Aldesleukin + GD2Bi-aATC + Sargramostim||Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma||Recruiting|